The EPS projection of United Therapeutics Corporation (NASDAQ:UTHR) for period quarter closed 2016-12-31 is $3.5.
The EPS estimates given 30-days and 1 week ago were $3.5 and $3.5, correspondingly. This number 90 and 60 days before was $3.5 and $3.5 respectively. Yet, from last week, the change in EPS prediction is 0%.
For the quarter ended 2 mean estimate is $3.5 based on 6 EPS estimations. As on 2016-07-28 estimated EPS was $4.52 showing surprise of $1.26, or 38.65%. Following the given predictions, the standard deviation is $0.2.
The upgrade count for EPS revisions was 0 a week earlier paralleled to negative revisions of 0. In last 60-days and 1- month, the upgrade in EPS reviews were 0 and 0 correspondingly, though for a quarter and 120-days ago, it was 2 and 2 in that sequence.
The negative reviews of EPS in the last 60-days and 1-month were 0 and 0 in that order. But, a quarter and 120-days ago, this numeral was 3 and 3 correspondingly.
EPS reviews downgrade and upgrade for last 18 days were 3 and 2, correspondingly.
Quarterly Sales Estimates
The mathematical mean of apparent yearly sales of United Therapeutics Corporation (NASDAQ:UTHR) is $420.204 and the median is $425.7. The estimate is stated by 5 analysts for the fiscal 2016.
The highest yearly projection is $427.44 and lowest sales mark is $406. This results a standard deviation of $9.173.
Almost 5 have reviewed sales target for better in the past week and 5 have downgraded forecasts. Subject to the stated estimates, the intended change in disclosed target from the past week is 0%.
Nearly 5 revised sales predictions for better over the past month and 5 have downgraded forecasts. It suggests an average deviation of 0.344% across given estimates.
Just about 5 have revised sales forecast up over the quarter and 5 have downgraded forecasts, hinting to a deviation of -1%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...